Adlai Nortye (ANL) Long-Term Investments (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Long-Term Investments of $4.2 million for Q4 2025, up 60600.0% year-over-year from N/an in Q4 2024, and up 1.82% quarter-over-quarter from $4.2 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Long-Term Investments (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Long-Term Investments for 4 consecutive years, with $4.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Investments rose 60600.0% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (up 60600.0% YoY), while the FY2025 annual figure was $4.2 million, up 60600.0% from the prior year.
- Long-Term Investments climbed to $4.2 million in Q4 2025 per ANL's latest filing, from $4.2 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $21.3 million in Q4 2022 and bottomed at $7000.0 in Q4 2023.
- Historically, Long-Term Investments has averaged $5.7 million across 4 years, with a median of $4.2 million in 2024.
- Annual changes were most pronounced in 2023 — Long-Term Investments plunged 99.97% — and 2025, when it soared 60600.0%.
- Adlai Nortye's Long-Term Investments stood at $21.3 million in 2022, then slumped by 99.97% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024, then jumped by 60600.0% to $4.2 million in 2025.
- Business Quant data shows ANL's Long-Term Investments at $4.2 million in Q4 2025, $4.2 million in Q2 2025, and $7000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 4.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.34 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Jun 30, 2025 | 4.17 Mn |
| Dec 31, 2024 | 4.16 Mn |
| Jun 30, 2024 | 4.20 Mn |
| Dec 31, 2023 | 129.71 Mn |
| Dec 31, 2022 | 94.30 Mn |